In general, Dawnbreaker health does not prescribe controlled substances. We have two notable exceptions we may prescribe if medically indicated
We prescribe Dual Orexin Receptor Antagonists (DORAs) for insomnia if indicated because of the unique effectiveness of these medications for treatment resistant insomnia and lower observed abuse potential than many alternatives.
- Real-world pharmacovigilance analyses and Controlled Substances Act–focused reviews suggest DORAs may be associated with lower real-world abuse/misuse risk than Schedule IV benzodiazepines and Z-drugs.1,2
- In a human abuse potential study, daridorexant at its therapeutic dose showed lower “drug-liking” than zolpidem.3
The Three FDA Approved DORAs are Belsomra — suvorexant, Dayvigo — lemborexant, Quviviq — daridorexant
We prescribe testosterone because it is a naturally occurring chemical that is testable in patients with a standard minimum cutoff beyond which it very defensible to manage.
- Endocrine Society guidance recommends testosterone therapy only for men with symptoms/signs of hypogonadism and consistently low morning total testosterone on repeat testing (for CDC‑standardized assays, the lower limit of normal is ~264 ng/dL [9.2 nmol/L]).⁴
- Patients started on therapy should be monitored for clinical response and adverse effects (including hematocrit and prostate safety assessment when indicated).⁴
We do not prescribe controlled substances to treat ADHD. However given our clinic’s focus on tailored psychopharmacology, we can discuss these medications in an academic manner and provide suggestions or diagnosis (per criteria), you can take to another provider. If indicated we can prescribe non controlled substances for ADHD either alone or to augment current treatments.
References
- Moline M, Asakura S, Beuckmann C, et al. The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology (Berl). 2023;240(4):699-711. doi:10.1007/s00213-023-06320-y
- Saskin P, McCall WV, Neubauer D, et al. Real-world data on the abuse potential of medications for the treatment of insomnia: a disproportionality analysis of the FAERS database. Front Pharmacol. 2025. Provisionally accepted. doi:10.3389/fphar.2025.1735180
- Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep. 2022;45(3):zsab224. doi:10.1093/sleep/zsab224
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229
